At present, immunotherapy targeting immune checkpoints, especially programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and CTLA-4 blockers have become feasible in the treatment of many malignant tumors (Cai et al., 2019). Here, PDCD1 is linked to cancer.